A LinkedIn post from Lorikeet highlights a podcast discussion between Steve Hind and Tim Doyle, CEO of Eucalyptus, on scaling telehealth patient support with artificial intelligence. According to the post, Eucalyptus operates across four countries with varying regulations and sensitive health inquiries, yet pursued AI-driven support in this complex context.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post suggests that AI now resolves 60–70% of support tickets end-to-end, with more complex cases routed to human agents, and that aggregate customer satisfaction reportedly improved by 10 points. One insight cited is that patients are said to be 50% more likely to prefer AI when questions are personal or embarrassing, indicating that AI may expand the range of issues patients are willing to address.
The commentary in the post frames return on investment in AI support as linked to tackling difficult, workflow-intensive use cases rather than simple FAQ automation. For investors, this may signal Lorikeet’s focus on deeper product integration in regulated, high-friction environments, which could support premium pricing, stickier deployments, and competitive differentiation if such outcomes can be replicated across additional clients.
If similar performance and satisfaction metrics are achieved broadly, the approach described could enhance the value proposition of AI-driven support in telehealth and adjacent regulated verticals. This positioning may place Lorikeet to benefit from growing demand for automation that both reduces operating costs and addresses patient comfort with sensitive topics, potentially strengthening its long-term industry standing.